Emisphere Technologies, Inc. (EMIS) and Alchemia to Research an Oral Formulation of Fondaparinux with Eligen(R) Technology  
3/18/2010 10:17:46 AM

CEDAR KNOLLS, N.J. & BRISBANE, Australia--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) today announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere’s Eligen® Technology.